Cargando…
Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter
In atrial arrhythmias, amiodarone is usually given either intravenously for acute management, requiring in-hospital monitoring, or orally for chronic control, as doses given 60 times per half-life, requiring weeks to reach full effect. A high-risk, 245-kg male with heart failure exacerbated by atria...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402954/ https://www.ncbi.nlm.nih.gov/pubmed/36035739 http://dx.doi.org/10.1016/j.cjco.2022.04.006 |
_version_ | 1784773259986731008 |
---|---|
author | Le, Vincent K. Kavanagh, Katherine M. Raj, Satish R. Pollak, P. Timothy |
author_facet | Le, Vincent K. Kavanagh, Katherine M. Raj, Satish R. Pollak, P. Timothy |
author_sort | Le, Vincent K. |
collection | PubMed |
description | In atrial arrhythmias, amiodarone is usually given either intravenously for acute management, requiring in-hospital monitoring, or orally for chronic control, as doses given 60 times per half-life, requiring weeks to reach full effect. A high-risk, 245-kg male with heart failure exacerbated by atrial flutter was successfully cardioverted using an atypically large, 8000-mg oral amiodarone dose. The only adverse effect was transient sinus arrest, which did not require intervention, only 24 hours of inpatient monitoring. Amiodarone’s unique pharmacokinetics, including its long elimination half-life and its extensive distribution into a large volume of adipose tissue, make high-dose oral amiodarone boluses a reasonable strategy for cardioversion of atrial arrhythmias. |
format | Online Article Text |
id | pubmed-9402954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-94029542022-08-26 Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter Le, Vincent K. Kavanagh, Katherine M. Raj, Satish R. Pollak, P. Timothy CJC Open Case Report In atrial arrhythmias, amiodarone is usually given either intravenously for acute management, requiring in-hospital monitoring, or orally for chronic control, as doses given 60 times per half-life, requiring weeks to reach full effect. A high-risk, 245-kg male with heart failure exacerbated by atrial flutter was successfully cardioverted using an atypically large, 8000-mg oral amiodarone dose. The only adverse effect was transient sinus arrest, which did not require intervention, only 24 hours of inpatient monitoring. Amiodarone’s unique pharmacokinetics, including its long elimination half-life and its extensive distribution into a large volume of adipose tissue, make high-dose oral amiodarone boluses a reasonable strategy for cardioversion of atrial arrhythmias. Elsevier 2022-04-28 /pmc/articles/PMC9402954/ /pubmed/36035739 http://dx.doi.org/10.1016/j.cjco.2022.04.006 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Le, Vincent K. Kavanagh, Katherine M. Raj, Satish R. Pollak, P. Timothy Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter |
title | Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter |
title_full | Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter |
title_fullStr | Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter |
title_full_unstemmed | Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter |
title_short | Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter |
title_sort | tolerance of high-dose oral amiodarone for cardioversion of atrial flutter |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402954/ https://www.ncbi.nlm.nih.gov/pubmed/36035739 http://dx.doi.org/10.1016/j.cjco.2022.04.006 |
work_keys_str_mv | AT levincentk toleranceofhighdoseoralamiodaroneforcardioversionofatrialflutter AT kavanaghkatherinem toleranceofhighdoseoralamiodaroneforcardioversionofatrialflutter AT rajsatishr toleranceofhighdoseoralamiodaroneforcardioversionofatrialflutter AT pollakptimothy toleranceofhighdoseoralamiodaroneforcardioversionofatrialflutter |